Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02114697 · ClinicalTrials.gov registry record · Phase 4
Accelerated Atherosclerosis in High Risk Population Groups: An Assessment by Magnetic Resonance Imaging
A Phase 4 study, sponsored by Emory University.
- Terminated
- Registry status
- Phase 4
- Development phase
- 9
- Enrollment target
NCT02114697 is a Phase 4 study that was terminated before completion, run by Emory University. The registered enrollment target is 9 participants.
The verdict
NCT02114697, a Phase 4 study, was terminated before completion, sponsored by Emory University.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 9 participants
- Enrollment target
Study Summary
The goal of this study is to assess a slimy substance that settles/deposits along blood vessel wall. This slimy substance is called plaque. Plaque could be made up of fat, calcium or both. Plaque deposition narrows the vessels. This leads to decreased blood flow to various parts of body. Blood vessels include vessels that supply to heart (coronary), vessels to brain (carotid), vessels to kidneys (renal) and vessels to legs (femoral). Decreased blood flow causes symptoms such as brain stroke, heart attack, leg pain. Similarly individuals at risk of cardiovascular disease can have certain markers elevated in their blood that can be measured by simple blood tests. High or increased plaque deposition is seen in neck vessels of cancer patients who received radiation to chest or head and neck as part of their cancer treatment. Cancer survivors are at increased risk of plaque development and are therefore called high-risk population. Exercise +/- fat lowering medicine can potentially decrease plaque deposition and statins are one of the several fat lowering medications.
Interventions
- BEHAVIORAL Lifestyle modification
- DRUG Statin therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2014-04 |
| Est. Completion | 2017-07 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02114697
The ClinicalTrials.gov registry entry for NCT02114697 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Lifestyle modification is the first listed.
NCT02114697 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02114697 about?
NCT02114697 is a clinical study titled "Accelerated Atherosclerosis in High Risk Population Groups: An Assessment by Magnetic Resonance Imaging". The goal of this study is to assess a slimy substance that settles/deposits along blood vessel wall. This slimy substance is called plaque. Plaque could be made up of fat, calcium or both. Plaque deposition narrows the vessels. This leads to decreased blood flow to various parts of body. Blood vesse...
What is the current status of trial NCT02114697?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 9 participants. The study started on 2014-04. Estimated completion is 2017-07.
What interventions are being tested in trial NCT02114697?
The interventions under investigation include: Lifestyle modification (BEHAVIORAL), Statin therapy (DRUG).
Who is sponsoring clinical trial NCT02114697?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.